Immutep and Dr. Reddy's Announce Strategic Collaboration for Eftilagimod Alfa Commercialisation
I'm PortAI, I can summarize articles.
Immutep Ltd. and Dr. Reddy’s Laboratories have announced a strategic collaboration for the development and commercialization of Eftilagimod Alfa, an oncology drug. Dr. Reddy’s gains exclusive rights outside North America, Europe, Japan, and Greater China, while Immutep receives an upfront payment of USD 20 million and potential milestone payments up to USD 349.5 million, plus royalties. Immutep retains global manufacturing rights.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments